{"id":"pcv10-and-dtap","safety":{"commonSideEffects":[{"rate":"10–50%","effect":"Injection site pain, redness, or swelling"},{"rate":"10–30%","effect":"Fever"},{"rate":"5–20%","effect":"Irritability or fussiness"},{"rate":"5–15%","effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCV10 (pneumococcal conjugate vaccine) contains polysaccharide antigens from 10 serotypes of Streptococcus pneumoniae conjugated to a protein carrier, eliciting both T-cell and B-cell responses. DTaP (diphtheria, tetanus, acellular pertussis) contains inactivated toxins and acellular pertussis antigens that trigger protective antibody production against these three bacterial pathogens. Together, the combination vaccine provides immunological protection against invasive pneumococcal disease and pertussis-related illnesses.","oneSentence":"PCV10 and DTaP is a combination vaccine that stimulates the immune system to produce antibodies against pneumococcal serotypes and diphtheria, tetanus, and pertussis toxins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:03.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by serotypes in PCV10"},{"name":"Prevention of diphtheria, tetanus, and pertussis in infants and children"}]},"trialDetails":[{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT01028326","phase":"PHASE4","title":"PCV10 Reactogenicity and Immunogenicity Study - Malindi","status":"UNKNOWN","sponsor":"KEMRI-Wellcome Trust Collaborative Research Program","startDate":"2010-01","conditions":"Pneumococcal Pneumonia","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Synflorix"],"phase":"marketed","status":"active","brandName":"PCV10 and DTaP","genericName":"PCV10 and DTaP","companyName":"KEMRI-Wellcome Trust Collaborative Research Program","companyId":"kemri-wellcome-trust-collaborative-research-program","modality":"Biologic","firstApprovalDate":"","aiSummary":"PCV10 and DTaP is a combination vaccine that stimulates the immune system to produce antibodies against pneumococcal serotypes and diphtheria, tetanus, and pertussis toxins. Used for Prevention of invasive pneumococcal disease caused by serotypes in PCV10, Prevention of diphtheria, tetanus, and pertussis in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}